By Dr Emmanuel Eni Amadi, PhD, MBA
Medical Scientist | Adult ADHD Clinician | GPhC Registered Pharmacist Independent Prescriber
7 November 2026 | Clinical Research & Evidence Commentary
A landmark UK clinical trial is investigating whether atomoxetine and metformin could offer new treatment possibilities for Alzheimer's disease. The implications extend beyond dementia to neuroscience, clinical pharmacology and the future of drug discovery.
1. A New Chapter in Alzheimer's Research
What if medicines already prescribed to millions of patients for entirely different conditions could help address one of medicine's greatest challenges: Alzheimer's disease?
On 22 October 2026, BBC medical editor Fergus Walsh reported the launch of an innovative UK clinical trial investigating two familiar medicines: atomoxetine, a non-stimulant medication used in attention deficit hyperactivity disorder (ADHD), and metformin, a first-line treatment for type 2 diabetes [1].
The trial, known as AD-SMART (Alzheimer's disease Systematic Multi-arm Adaptive Randomised Trial), represents a significant development in the search for treatments that could preserve memory, cognition and everyday functioning.
Led by Professor Paresh Malhotra and involving the UK Dementia Research Institute, Alzheimer's Research UK and major academic and NHS partners, AD-SMART aims to recruit approximately 1,200 participants across more than 30 UK sites [2,3].
The first treatment evaluations are expected in 2030.
For patients and families living with Alzheimer's disease, this research offers a reason for cautious optimism. For clinicians and medical scientists, it raises an important question:
Could treatments developed for one condition reveal therapeutic opportunities in another?
The answer remains uncertain. However, the scientific rationale is compelling enough to justify a large, carefully controlled clinical investigation.
2. Why Atomoxetine? The ADHD Connection
Atomoxetine is a selective noradrenaline reuptake inhibitor used in ADHD treatment. Unlike conventional stimulant medications, its principal pharmacological action is to inhibit the noradrenaline transporter, increasing noradrenergic signalling.
Why might this matter in Alzheimer's disease?
One area of growing scientific interest is the locus coeruleus, a small brainstem nucleus that provides much of the brain's noradrenergic innervation.
Noradrenaline is involved in attention, arousal, cognitive processing and the regulation of several biological pathways relevant to brain health.
Research suggests that the locus coeruleus is affected early in Alzheimer's pathology. Investigators are therefore exploring whether enhancing noradrenergic signalling could influence processes associated with neurodegeneration, including neuroinflammation and neuronal dysfunction [4].
This hypothesis has already undergone preliminary clinical testing.
In a phase II randomised crossover study published in Brain, Levey and colleagues investigated atomoxetine in 39 participants with mild cognitive impairment and biomarker evidence of Alzheimer's pathology [4].
The researchers observed reductions in cerebrospinal-fluid concentrations of total tau and phosphorylated tau, proteins associated with Alzheimer's disease pathology.
However, the study did not demonstrate significant improvements in cognition or clinical outcomes.
This distinction is essential.
A change in a biological marker is scientifically interesting, but it is not equivalent to demonstrating that a patient remembers more, functions more independently or experiences slower clinical deterioration.
AD-SMART offers an opportunity to investigate whether promising biological observations can translate into meaningful patient benefits.
3. Why Metformin? The Metabolic Connection
Metformin has been used extensively in the management of type 2 diabetes. Its principal clinical effects include reducing hepatic glucose production and improving glycaemic regulation.
Its possible relevance to Alzheimer's disease extends beyond blood glucose control.
Researchers are investigating the relationships between metabolic dysfunction, insulin signalling, cellular energy regulation and neurodegenerative processes.
These pathways are important because the brain depends on highly regulated energy metabolism to maintain neuronal and synaptic function.
Metformin has attracted interest as a potential repurposed therapy because it may influence cellular energy pathways and other biological processes implicated in Alzheimer's disease [3,5].
Nevertheless, the clinical evidence remains mixed.
A systematic review and meta-analysis by Hui and colleagues examined associations between diabetes medicines and subsequent dementia or cognitive decline. Findings for metformin were inconsistent, highlighting the limitations of drawing causal conclusions from observational research [5].
It would therefore be premature to describe metformin as a proven Alzheimer's treatment.
The key question is not whether metformin is beneficial in diabetes, but whether it can produce clinically meaningful benefits in people already living with Alzheimer's disease.
That is precisely the type of question AD-SMART is designed to investigate.
4. The Real Innovation: Testing Multiple Medicines More Efficiently
The significance of AD-SMART lies not only in the medicines being investigated but also in the trial's design.
Traditional clinical trials frequently assess one investigational treatment against a separate control group. Establishing successive trials can require substantial time, funding and infrastructure.
AD-SMART uses a multi-arm, multi-stage adaptive platform design.
This allows several treatments to be evaluated within one coordinated trial infrastructure, using a shared placebo comparison group.
Treatments showing insufficient promise can be discontinued following planned interim assessments, while new candidate medicines may be introduced [2,3].
The approach has important potential advantages:
More efficient use of research infrastructure and participant recruitment.
Faster assessment of several therapeutic hypotheses.
Earlier discontinuation of treatments unlikely to provide benefit.
Greater flexibility to investigate additional candidate medicines.
Potential reductions in the time and cost of clinical development.
The research consortium suggests this approach could more than halve the time required to evaluate potential treatments compared with conventional sequential approaches [2].
Importantly, faster research must not mean weaker evidence. Robust randomisation, appropriate controls, safety monitoring and clinically meaningful outcome measures remain fundamental.
5. What Will Researchers Actually Measure?
For patients and carers, the most important outcomes extend beyond laboratory results.
AD-SMART will examine whether treatment affects cognition, everyday activities and quality of life.
Participants will undergo clinical assessments over approximately 18 months, including tests of memory and thinking, functional evaluations and safety monitoring. The study also includes biological investigations and imaging assessments where appropriate [3,6].
These measures help distinguish three fundamentally different outcomes:
Biological activity: Does the medicine affect a pathway associated with Alzheimer's disease?
Clinical effectiveness: Does the medicine improve or preserve memory, thinking or everyday functioning?
Patient-centred benefit: Does the treatment help individuals maintain independence and quality of life without unacceptable adverse effects?
A successful intervention must ultimately demonstrate benefits that matter to patients, balanced against treatment risks.
6. What Does This Mean for ADHD Clinicians and Pharmacists?
As a medical scientist, UKAAN-trained Adult ADHD Clinician and Pharmacist Independent Prescriber, I find the investigation of atomoxetine particularly significant.
The medicine is already familiar within ADHD pharmacotherapy. Its inclusion in Alzheimer's research illustrates how understanding a medicine's mechanism of action can generate hypotheses extending beyond its established therapeutic indication.
However, there are important professional boundaries.
Atomoxetine is not currently an established treatment for Alzheimer's disease. Metformin is not an established treatment for Alzheimer's disease either.
Neither medicine should be initiated, substituted or continued specifically for Alzheimer's disease on the assumption that AD-SMART has already demonstrated benefit.
Clinical decisions must remain grounded in approved indications, individual patient assessment, relevant prescribing guidance and the evolving evidence base.
For pharmacists, this research also highlights the importance of medicines optimisation, interaction assessment, adverse-effect surveillance and multidisciplinary collaboration, particularly in older adults with multiple medical conditions.
The broader lesson is that clinical pharmacology can contribute to scientific innovation without bypassing the need for rigorous evidence.
7. A Wider Opportunity for Neuroscience and Healthcare Innovation
AD-SMART demonstrates how research into apparently different conditions can converge around shared biological pathways.
ADHD, type 2 diabetes and Alzheimer's disease are distinct conditions. Their clinical presentations, underlying mechanisms and treatment objectives must not be conflated.
Nevertheless, studying noradrenergic signalling, metabolic regulation and neuroinflammatory pathways may reveal useful connections across neurological and metabolic research.
This is the promise of drug repurposing: established medicines may provide starting points for investigating new therapeutic applications.
It does not guarantee success. Many biologically plausible treatments fail to produce meaningful clinical benefits.
But when promising hypotheses are tested through well-designed trials, medicine advances regardless of whether an individual drug ultimately succeeds.
8. My Clinical and Scientific Perspective
My professional interest in this development draws upon more than 26 years in pharmacy and healthcare, approximately a decade of mental-health-related clinical experience, specialist ADHD Clinician training and my academic background in a PhD medical sciences and nanotoxicology.
My doctoral research reinforced the importance of examining biological mechanisms, interpreting experimental findings critically and distinguishing laboratory observations from demonstrated clinical outcomes.
AD-SMART exemplifies that principle.
An encouraging biomarker result is the beginning of a scientific investigation, not its conclusion.
What matters now is whether atomoxetine, metformin or future medicines evaluated through this platform can produce measurable improvements in the lives of people living with Alzheimer's disease.
9. Conclusion:
A Breakthrough in Research Design - Not Yet a Breakthrough Treatment
The launch of AD-SMART is a meaningful milestone in UK dementia research.
It brings together academic institutions, NHS research sites, clinicians, scientists, patients and research organisations around a more efficient way of investigating potential treatments.
The selection of atomoxetine and metformin demonstrates the value of looking again at established medicines through the lens of contemporary neuroscience and metabolic research.
But the central scientific question remains unanswered:
Can these medicines preserve cognition, everyday functioning or quality of life in people living with Alzheimer's disease?
Until robust trial results become available, optimism must remain accompanied by scientific caution.
For the millions of people affected by dementia worldwide, the opportunity is not merely to discover another drug.
It is to discover, through rigorous research, which treatments genuinely make a difference.
References
[1] Walsh, F. (2026) ‘Diabetes and ADHD drugs to be tested on Alzheimer's patients in new study’. BBC News, 22 October 2026. Article information supplied from the BBC report.
[2] Imperial College London (2026) ‘New UK trial aims to find answers more quickly for Alzheimer's disease’, 22 October. Available at: https://www.imperial.ac.uk/news/articles/medicine/brain-sciences/2026/new-uk-trial-aims-to-find-answers-more-quickly-for-alzheimers-disease-/
[3] Alzheimer's Research UK (2026) ‘AD-SMART: The new clinical trial speeding up the search for Alzheimer's treatments’, 22 October. Available at: https://www.alzheimersresearchuk.org/news/ad-smart-the-new-clinical-trial-speeding-up-the-search-for-alzheimers-treatments/
[4] Levey, A.I. et al. (2022) ‘A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment’. Brain, 145(6), pp. 1924–1938. https://doi.org/10.1093/brain/awab452
[5] Hui, E.K., Mukadam, N., Kohl, G. and Livingston, G. (2025) ‘Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis’. Journal of Alzheimer's Disease, 104(3), pp. 627–648. https://doi.org/10.1177/13872877251319054
[6] AD-SMART (2026) AD-SMART national clinical trial: Official study website. Available at: https://www.adsmarttrial.org/
Clinical disclaimer: This article is an educational and scientific commentary, not individual medical advice. The investigational use of atomoxetine and metformin for Alzheimer's disease remains subject to clinical trial evaluation. Patients should not alter prescribed medicines without consulting their treating clinician.
Dr Emmanuel Eni Amadi, PhD, MBA
Medical Scientist | Adult ADHD Clinician | GPhC Registered Pharmacist Independent Prescriber | UKAAN-Trained
